VCEL
Vericel Corporation
Biotechnology · Healthcare · United States
44.54
close · 2026-08-13
value
29
cheaper than peers29
quality
69
stronger fundamentals69
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 7.75× | 66 |
| price to book | 6.16× | 44 |
| forward P/E | 52.65× | 16 |
| EV to EBITDA | 73.47× | 16 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 7.2% | 76 |
| operating margin | 0.6% | 74 |
| revenue growth | 22.5% | 46 |
| debt to equity | 25.2% | 43 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $55.5M |
| employees | 398 |
| first trade | 1997-02-04 |
| next earnings | 2026-07-30 |
| fundamentals updated | 2026-08-04 |